
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the two announcements, the company’s stock, listed on the New York Stock Exchange (NYSE), closed 37. …